Access Official Technical PDF

Share Summary:LinkedInEmail

A bankruptcy-driven business sale can affect more than ownership of production assets. Suppliers, dealers, service providers and other business partners may also face changes to the agreements that support day-to-day operations. Briggs & Stratton Corporation’s 2020 Chapter 11 sale process illustrates how an executory contract assignment may be addressed when a debtor seeks to transfer contracts to a buyer. For industrial companies and their counterparties, the notice highlights the importance of reviewing contract schedules, proposed cure costs and deadlines rather than assuming an agreement will continue unchanged.

What the Briggs & Stratton notice set out

In August 2020, the Bankruptcy Court for the Eastern District of Missouri approved bidding procedures for a proposed sale of substantially all of the debtors’ assets and certain equity interests. A binding stalking horse bid had been submitted by Bucephalus Buyer, LLC, an affiliate of KPS Capital Partners. The bid remained subject to higher or otherwise better offers under the approved procedures.

As part of that process, the debtors issued a notice to counterparties whose agreements might be assumed and assigned to a successful bidder. The accompanying schedule identified contracts by debtor, counterparty, contract description and proposed cure amount. The listed agreements covered a broad range of relationships, including dealer, service, supply, tooling, equipment, licensing and confidentiality agreements. Inclusion on the schedule did not guarantee that a contract would ultimately be assumed or transferred.

This distinction matters in industrial settings. A schedule can flag a possible change to a supplier, maintenance, distribution or equipment-related relationship, but it is not itself confirmation that a buyer will take on that agreement. The notice expressly stated that a successful bidder was not bound to accept assignment of every listed purchased contract.

How cure costs factor into contract assignment

When seeking to assume and assign a contract, a debtor may need to address defaults that exist under the agreement. The notice called the proposed amounts required to address monetary defaults “Cure Costs” and provided a figure for each scheduled contract. Many entries showed a proposed amount of zero, while others listed nonzero amounts. These were proposed figures in the notice, with balances stated as of August 6, 2020—not a general statement about the status of every contract or a guarantee of the final amount.

Counterparties who disputed a proposed cure amount had to file a Cure Objection with the court and serve designated notice parties by the stated deadline: September 4, 2020, at 5:00 p.m. Central Time. The notice warned that a counterparty that missed the deadline would be barred from later objecting to the stated cure amount and from asserting additional cure amounts covered by the notice.

For a supplier or service provider, the operational takeaway is straightforward: reconcile the proposed amount against the relevant agreement and account records, identify any disputed defaults, and follow the required filing and service process. Simply raising a concern informally would not, under the notice, preserve the right to object if the dispute remained unresolved.

Adequate assurance and future performance

Contract assumption and assignment also raised a separate question: whether the proposed assignee could provide adequate assurance of future performance. The notice said that, upon a counterparty’s request, the debtors would direct it to counsel for the stalking horse bidder to discuss information about future performance. At the sale hearing, the bidder would provide additional financial and commercial information to the extent the court required.

A counterparty objecting to the proposed form of adequate assurance also had to file and serve an objection by the September 4 deadline. The notice warned that failure to do so would bar a later objection on that ground and that the successful bidder or designated assignee would be deemed to have provided adequate assurance under the cited Bankruptcy Code provision.

For operations teams, the issue is not only whether a buyer intends to continue a relationship. It is also whether the proposed transfer raises concerns about the assignee’s ability to meet the agreement’s obligations. Relevant contract-specific questions may include what performance is required and what information the process makes available. The notice does not provide a universal standard for resolving such questions; it describes the procedure used in this case.

Objections, deadlines and changing contract lists

The notice separated three types of objections:

  • Cure objections: disputes about the proposed amount needed to address monetary defaults.
  • Adequate assurance objections: disputes about the proposed assignee’s assurance of future performance.
  • Assumption or assignment objections: other objections to the proposed assumption or transfer of a scheduled contract.

Each category had a filing and service requirement and the same stated deadline. The debtors also invited counterparties to try to resolve disputes consensually before that deadline, while making clear that unresolved disputes required a timely formal objection to preserve rights.

The contract list could also change. Under the procedures described, the debtors could add or remove contracts before entry of the sale approval order by filing and serving a supplemental notice. The notice further stated that contracts could be added after the sale closed through a supplemental notice. Accordingly, counterparties needed to monitor formal notices rather than treat the initial schedule as final.

Practical implications for industrial businesses

A bankruptcy sale can create uncertainty around commercial relationships that support manufacturing, distribution and service operations. Counterparties reviewing a notice like this can usefully:

  • Confirm whether the relevant legal entity and agreement appear on the contract schedule.
  • Check the listed contract description and proposed cure amount against their own records.
  • Track deadlines and follow the specified court filing and service requirements if disputing the proposed treatment.
  • Request information about the proposed assignee’s future performance where the process allows.
  • Continue monitoring for supplemental notices that may add, remove or otherwise update scheduled contracts.

The Briggs & Stratton notice is a historical example of one court-supervised sale process, not a substitute for reviewing the applicable order, procedures and legal advice in a particular case. Its practical lesson for industrial counterparties is that contract continuity should be treated as a process to verify—not an assumption. Timely review of the agreement, cure calculation, proposed assignee and formal notices can help business and operations teams understand what may change and when they need to respond.

Access Official Technical PDF

About The Author